Nurix Therapeutics Inc (NRIX)
12.78
+0.05
(+0.39%)
USD |
NASDAQ |
May 03, 16:00
12.78
0.00 (0.00%)
After-Hours: 20:00
Nurix Therapeutics Profit Margin (Quarterly): -250.3% for Feb. 29, 2024
Profit Margin (Quarterly) Chart
Historical Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| February 29, 2024 | -250.3% |
| November 30, 2023 | -276.8% |
| August 31, 2023 | -200.3% |
| May 31, 2023 | -79.14% |
| February 28, 2023 | -321.1% |
| November 30, 2022 | -688.7% |
| August 31, 2022 | -423.6% |
| May 31, 2022 | -397.1% |
| February 28, 2022 | -442.1% |
| November 30, 2021 | -509.8% |
| Date | Value |
|---|---|
| August 31, 2021 | -281.3% |
| May 31, 2021 | -372.0% |
| February 28, 2021 | -484.4% |
| November 30, 2020 | -297.7% |
| August 31, 2020 | -453.3% |
| May 31, 2020 | |
| February 29, 2020 | -432.6% |
| November 30, 2019 | -726.0% |
| August 31, 2019 | -22.94% |
Profit Margin Definition
Profit Margin is calculated using Net Income/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into profit. An analyst looking at profit margin might look for a higher profit margin relative to other comparable companies as well as a profit margin that is growing.
Profit Margin (Quarterly) Range, Past 5 Years
-726.0%
Minimum
Nov 2019
-22.94%
Maximum
Aug 2019
-370.0%
Average
-384.6%
Median
Profit Margin (Quarterly) Benchmarks
| Gilead Sciences Inc | -62.37% |
| ALX Oncology Holdings Inc | -- |
| Vanda Pharmaceuticals Inc | -5.30% |
| GlycoMimetics Inc | -90.79K% |
| Immunic Inc | -- |
Profit Margin (Quarterly) Related Metrics
| Return on Equity | -63.65% |
| Return on Assets | -42.64% |
| Return on Invested Capital | -63.65% |
| Operating Margin (Quarterly) | -272.6% |
| Return on Net Operating Assets | -392.9% |